Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MMRC Horizon One: A Phase II Randomized Adaptive Platform Trial Evaluating Novel Therapies in Relapsed or Refractory Multiple Myeloma (MMRC-099)

NCT06171685 is registered in ClinicalTrials.gov with Multiple Myeloma Research Consortium as lead sponsor.

NCT NCT06171685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06171685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MMRC Horizon One: A Phase II Randomized Adaptive Platform Trial Evaluating Novel Therapies in Relapsed or Refractory Multiple Myeloma (MMRC-099)
Lead sponsor
Multiple Myeloma Research Consortium
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 17, 2024
Completion date
July 31, 2030
Enrollment
300 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma, relapse multiple myeloma